Latest Period
Q2 2026
Security Snapshot
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) Institutional Ownership
CUSIP: 52886X107
13F Institutional Holders and Ownership History from Q4 2023 to Q2 2026
Institutions Reporting
142
Shares (Excl. Options)
88,240,530
Price
$4.66
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- LXEO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 88,240,530
- Total 13F value
- $410,870,572
- Portfolio coverage rank
- 0%
- Share change
- +9,214,336
- Value change
- +$39,183,118
- Number of holders
- 142
- Shares outstanding
- 78,780,792
- SEC-reported price per share
- $4.66
- Insider filing price
- $4.66
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LXEO - Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 52886X107.
- 142 institutions reported positions in Q2 2026.
- 19 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 138 to 142 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $458,111,449 to $410,870,572.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 142 institutions filings for Q2 2026.
Security key
52886X107
Latest holder period
Q2 2026
13F holders
142
13D/G owners
19
CIK / CUSIP context first
Open Q2 2026 holders
LXEO full holder history
Lexeo Therapeutics, Inc. SEC filings
Lexeo Therapeutics, Inc. company facts
Lexeo Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 52886X107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
19
Security
LXEO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | 10% | +3% | $36,083,831 | +$3,073,568 | 7,844,311 | +9.3% | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 |
| JANUS HENDERSON GROUP PLC | 10% | -12% | $65,914,563 | +$10,720,599 | 7,291,434 | +19% | JANUS HENDERSON GROUP PLC | 28 Nov 2025 |
| Affinity Asset Advisors, LLC | 8.4% | +19% | $30,704,600 | +$6,703,364 | 6,674,913 | +28% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.7% | $32,573,226 | 5,674,778 | SUVRETTA CAPITAL MANAGEMENT, LLC | 06 Apr 2026 | |||
| CITADEL ADVISORS LLC | 7.4% | -22% | $40,851,767 | +$1,219,315 | 5,498,219 | +3.1% | Kenneth Griffin | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 6.9% | $33,200,000 | 5,000,000 | RA Capital Management, L.P. | 20 Oct 2025 | |||
| BlackRock, Inc. | 6.7% | +68% | $48,518,087 | +$26,984,571 | 4,885,814 | +125% | BlackRock, Inc. | 31 Dec 2025 |
| STATE STREET CORP | 5.5% | $20,031,965 | 4,354,775 | STATE STREET CORPORATION | 30 Jun 2026 | |||
| Paradigm Biocapital Advisors LP | 5.3% | -38% | $19,206,757 | -$9,240,259 | 4,175,382 | -32% | Paradigm BioCapital Advisors LP | 30 Jun 2026 |
| Vestal Point Capital, LP | 7.5% | +25% | $27,338,885 | +$5,903,896 | 4,117,302 | +28% | Vestal Point Capital, LP | 30 Sep 2025 |
| Frazier Life Sciences Public Fund, L.P. | 5.1% | -10% | $27,478,154 | +$4,642,294 | 3,698,271 | +20% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| ORBIMED ADVISORS LLC | 4.1% | $14,734,030 | 3,203,050 | OrbiMed Advisors LLC | 30 Jun 2026 | |||
| Longitude Capital Partners IV, LLC | 3.8% | $18,362,130 | 2,765,381 | Longitude Capital Partners IV, LLC | 30 Sep 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 3.2% | -42% | $15,362,583 | -$3,470,396 | 2,313,642 | -18% | Millennium Management LLC | 30 Sep 2025 |
| MIZUHO FINANCIAL GROUP INC | 6.6% | +13% | $8,109,362 | +$1,020,464 | 2,203,631 | +14% | Mizuho Financial Group, Inc. | 31 Mar 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.7% | $4,544,189 | 1,234,834 | Eventide Asset Management, LLC | 31 Dec 2024 | |||
| Omega Fund VI, L.P. | 3.6% | $4,359,460 | 1,184,636 | Omega Fund VI, L.P. | 31 Dec 2024 | |||
| D1 Capital Partners L.P. | 2.9% | $3,601,439 | 978,652 | D1 Capital Partners L.P. | 31 Mar 2025 | |||
| Adage Capital Management, L.P. | 0.7% | -85% | $875,667 | -$7,255,716 | 237,953 | -89% | Adage Capital Management, L.P. | 31 Mar 2025 |
As of 30 Jun 2026, 142 institutional investors reported holding 88,240,530 shares of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO). This represents 112% of the company’s total 78,780,792 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
99%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 8.1% | 6,384,200 | +411% | 0.62% | $29,718,451 |
| Affinity Asset Advisors, LLC | 7.4% | 5,807,611 | +15% | 1.3% | $27,034,429 |
| BlackRock, Inc. | 7.3% | 5,739,455 | +12% | 0% | $26,717,165 |
| RA CAPITAL MANAGEMENT, L.P. | 6.3% | 5,000,000 | 0% | 0.2% | $23,275,000 |
| Frazier Life Sciences Management, L.P. | 6.1% | 4,824,725 | +9% | 0.49% | $22,459,095 |
| STATE STREET CORP | 5.5% | 4,354,757 | +22% | 0% | $20,271,394 |
| Vestal Point Capital, LP | 5.5% | 4,320,000 | -3.5% | 0.47% | $20,109,600 |
| Paradigm Biocapital Advisors LP | 5.3% | 4,175,382 | -32% | 0.36% | $19,436,403 |
| Jupiter Topco LLC | 5% | 3,954,691 | 0% | 0.01% | $18,409,087 |
| ORBIMED ADVISORS LLC | 5% | 3,947,850 | +9.6% | 0.35% | $18,377,242 |
| CITADEL ADVISORS LLC | 4.9% | 3,898,570 | +1.7% | 0.01% | $18,147,843 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 3,125,893 | +4% | 0% | $14,551,032 |
| MILLENNIUM MANAGEMENT LLC | 3.6% | 2,833,622 | +76% | 0.01% | $13,190,510 |
| Woodline Partners LP | 3.2% | 2,500,532 | -9.1% | 0.04% | $11,639,976 |
| Balyasny Asset Management L.P. | 3.1% | 2,412,742 | +52% | 0.02% | $11,231,314 |
| GOLDMAN SACHS GROUP INC | 2.7% | 2,149,612 | +10% | 0% | $10,006,444 |
| 683 Capital Management, LLC | 2.4% | 1,875,000 | +56% | 0.8% | $8,728,124 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,747,959 | +15% | 0% | $8,138,547 |
| ADAR1 Capital Management, LLC | 2% | 1,565,950 | +6.7% | 0.35% | $7,289,497 |
| Avoro Capital Advisors LLC | 1.9% | 1,489,189 | -21% | 0.06% | $6,932,175 |
| Qube Research & Technologies Ltd | 1.7% | 1,376,222 | +196% | 0.01% | $6,406,313 |
| Nantahala Capital Management, LLC | 1.7% | 1,300,000 | +8.3% | 0.37% | $6,051,500 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 1,287,185 | +17% | 0% | $5,992,745 |
| Spruce Street Capital LP | 1.2% | 928,593 | 0% | 0.85% | $4,322,600 |
| Blackstone Inc. | 1.1% | 904,959 | 0% | 0.01% | $4,217,109 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
Q2 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 88,240,530 | $410,870,572 | +$39,183,118 | $4.66 | 142 |
| 2026 Q1 | 79,828,208 | $458,111,449 | +$6,784,198 | $5.74 | 138 |
| 2025 Q4 | 76,464,936 | $759,237,118 | +$269,440,399 | $9.93 | 147 |
| 2025 Q3 | 49,322,779 | $327,479,655 | +$52,645,662 | $6.64 | 108 |
| 2025 Q2 | 42,272,843 | $169,997,165 | +$59,022,508 | $4.02 | 90 |
| 2025 Q1 | 28,007,948 | $99,996,757 | -$11,520,766 | $3.47 | 88 |
| 2024 Q4 | 29,519,159 | $194,192,987 | -$4,086,062 | $6.58 | 89 |
| 2024 Q3 | 29,735,114 | $268,784,046 | +$10,322,355 | $9.04 | 67 |
| 2024 Q2 | 26,566,622 | $426,105,401 | +$55,254,655 | $16.04 | 57 |
| 2024 Q1 | 23,119,889 | $361,545,010 | +$108,427,159 | $15.68 | 54 |
| 2023 Q4 | 16,174,480 | $217,090,546 | +$217,090,546 | $13.42 | 31 |